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patients.2 Using a prior TNM classification sys‑
tem (7th edition), the 10 ‑year survival rates for 
stages I, II, III, and IV are 100%, 93%, 71%, and 
21%, respectively.
One ‑third of MTC cases result from a germline 
activating mutation in the proto ‑oncogene rear‑
ranged during transfection with a strong corre‑
lation between these mutations and their corre‑
sponding phenotypes.
Surgery is the only effective therapy in MTC. 
Undetectable basal serum calcitonin levels are 
a strong predictor of complete remission. When 
calcitonin levels are elevated, a careful evalua‑
tion and localization of postsurgical remnant tis‑
sue, early local recurrence, or metastases must be 
performed. Procalcitonin is an independent pre‑
dictor of MTC progression. High procalcitonin‑
‑to ‑calcitonin ratios correlate with a high risk of 
progressive disease and shorter progression ‑free 
Background Medullary thyroid carcinoma (MTC) 
is one of the most challenging cancers. Epidemi‑
ological studies have shown that during the past 
30 years neither a change in stage at diagnosis nor 
a significant improvement in survival has been 
achieved.1 Therefore, new diagnostic and thera‑
peutic strategies are needed for early detection 
of metastases or disease recurrence and tumor 
growth control.
MTC is a neuroendocrine neoplasm deriving 
from thyroid parafollicular C cells. It accounts 
for nearly 5% to 10% of thyroid malignancies. 
The overall prognosis for MTC patients is rela‑
tively good. One ‑third of patients present with 
a locally invasive tumor or clinically apparent 
spread to the regional lymph nodes. Distant me‑
tastases are present in 13% of patients at initial 
diagnosis and portend a poor prognosis. Recur‑
rent disease develops in approximately 50% of 
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and prolonged tumor uptake against low renal 
retention and was therefore selected for clinical 
evaluation.11 This derivative became a core sub‑
stance for a new project.
The GRAN ‑T‑MTC consortium operates within 
the ERA ‑NET on Translational Cancer Research 
(TRANSCAN) First Joint Transnational Call for 
Proposals 2011 (JTC 2011) on: “Validation of 
biomarkers for personalized cancer medicine.” 
It aims to develop a modern method of advanced 
MTC treatment, utilizing the phenomenon of 
overexpression of CCK2 receptor in this carcino‑
ma. The project is a phase I study with the 111In‑
‑labelled gastrin analogue DOTA‑(DGlu)6 ‑Ala‑
‑Tyr ‑Gly ‑Trp ‑Met ‑Asp ‑Phe ‑NH2 (CP04). The pos‑
itive results of the preclinical part of the project 
confirmed the possibility of administration of 
111In ‑CP04 to humans.12,13 The trial is registered 
at www.clinicaltrials.gov (ID: NCT03246659) and 
has been granted European Union Drug Regu‑
lating Authorities Clinical Trials number: 2015‑
‑000 805 ‑38. The project has been approved by 
the ethics committees in all centers participating 
in the clinical part of the project (Supplementa‑
ry material, Table S3).
The primary aim of the study is to evaluate 
the safety of the intravenous administration of 
CP04, to assess the biodistribution and dosimetry 
of the CCK2/gastrin receptor ligand (
111In ‑CP04) 
in cancerous and normal tissues of the human 
body, and to determine critical organs. The main 
secondary objectives are to evaluate the ability of 
CCK2/gastrin receptor ligand ‑scintigraphy to de‑
tect cancer lesions and to assess the ability of gel‑
ofusine co ‑injection.
The study consists of 2 phases: a preclinical 
part (Radiopharmaceutical development) and 
a clinical trial.
Radiopharmaceutical development (Work Pack-
age 1) The first step was to establish a clinically 
useful formulation for the radiolabeled peptide 
CP04. CP04 was prepared in GMP quality, and 
tests regarding stability, radiolabeling, and toxic‑
ity were carried out. A ready ‑to ‑use 111In ‑CP04 kit 
formulation was prepared, and the Investigation‑
al Medicinal Product Dossier was submitted to 
the National Authorities of the collaborators.12,13
Clinical trial (Work Package 2) Material and meth-
ods A sample size of 20 to 25 recruited patients 
with progressive or metastatic MTC is consid‑
ered appropriate for such a study, being a reason‑
able compromise to address the study’s purpose. 
The main inclusion criteria are: histologically doc‑
umented MTC, presence of more than 1 distant or 
nodal metastases confirmed with either 18F ‑fluo‑
rodeoxyglucose positron emission tomography–
computed tomography or contrast ‑enhanced CT 
or MRI, or calcitonin doubling time of less than 
2 years if there is no anatomical evidence of dis‑
ease, and the exclusion criteria: previous exter‑
nal beam radiation therapy within 2 years, preg‑
nancy or breastfeeding, known hypersensitivity 
survival. Serum carcinoembryonic antigen is 
a useful biomarker of MTC, especially in poor‑
ly differentiated metastatic cases with lost abil‑
ity to produce calcitonin. In some MTC patients 
with elevated postoperative calcitonin and short 
calcitonin doubling time, diagnostic and ther‑
apeutic options are limited due to unsuccess‑
ful disease localization with established imag‑
ing techniques, until the basal calcitonin level is 
at least 150 pg/ml.3-5 Therefore, a search for new 
targets and corresponding radionuclide imaging 
biomarkers is warranted.
There is still no efficient, universally recom‑
mended treatment regimen for advanced MTC. 
External beam therapy does not play a signifi‑
cant role. Conventional chemotherapy is of lim‑
ited value. Newer agents such as irinotecan (a 
topoisomerase I inhibitor) and 17 ‑AAG (a heat 
shock protein 90 inhibitor) are being evaluated 
in clinical trials.6
Tyrosine kinase inhibitors (TKIs) are currently 
being investigated (Supplementary material, Ta-
ble S1). Vandetanib and cabozatinib have been ap‑
proved for use in 2011 and 2012, respectively, by 
the Food and Drug Administration and Europe‑
an Medicines Agency. The low rate of partial re‑
sponses to TKI therapy and absence of complete 
responses in any of the various trials of mono‑
therapy emphasize the need for new, more effec‑
tive agents with acceptable toxicity.7
In clinical practice, evaluation of patients with 
MTC engages every available diagnostic option. 
Anatomic imaging (ultrasound, computed tomog‑
raphy [CT], or magnetic resonance imaging [MRI]) 
and numerous molecular imaging methods (pos‑
itron emission tomography computed tomogra‑
phy and single ‑photon emission computed tomog‑
raphy–computed tomography [SPECT‑CT]; Sup‑
plementary material, Table S2) have been used to 
localize recurrence or metastases of MTC. How‑
ever, there are still many patients with negative 
imaging results.
The cholecystokinin 2 (CCK2) receptor is over‑
expressed in over 90% of MTC cases.8 Some of 
the CCK2 receptor–related peptides were tested in 
clinical pilot studies in humans. Receptor target‑
ing was achieved to some extent in CCK2/gastrin 
receptor expressing tissues and, most impor‑
tantly, in tumor tissue with a high tumor ‑to‑
‑background ratio. The CCK ‑2/gastrin receptors 
are also a promising target for peptide receptor 
radionuclide therapy (PRRT) as the peptide can 
be labeled with either a γ‑ or β ‑emitting radionu‑
clide such as 90Y and 177Lu.
In an attempt to produce therapeutic options 
with CCK2/gastrin receptor–binding radiolabeled 
analogues, further research was initiated and 
coordinated within the European COST Action 
BM0607 “Targeted Radionuclide Therapy.”9,10 In 
these comparative studies, one derivative, name‑
ly DOTA ‑DGlu ‑DGlu ‑DGlu ‑DGlu ‑DGlu ‑DGlu ‑Ala‑
‑Tyr ‑Gly ‑Trp ‑Met ‑Asp ‑Phe ‑NH2 (CP04), showed 
the most promising characteristics: high meta‑
bolic stability and receptor affinity with a high 
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Discussion The main goal of the study is to trans‑
late the preclinical research results into the pro‑
tocols confirming the usefulness of the peptide 
targeting CCK ‑2/gastrin receptors as a diagnos‑
tic and potentially also a therapeutic tool. Among 
the several new biomarkers investigated in recent 
years, the CP04 showed good stability and affin‑
ity to CCK ‑2/gastrin receptor in vitro, as well as 
favorable biodistribution and pharmacokinetic 
properties in vivo. For these reasons, it has been 
selected for the current study. CCK ‑2/gastrin re‑
ceptors may become viable targets for radionu‑
clide scintigraphy and PRRT, while nephrotoxicity 
and myelotoxicity will be minimized. In the last 
2 decades, the somatostatin receptors were in‑
strumental to implementing peptide receptor– 
–mediated radionuclide diagnosis and therapy 
into clinical practice. It can be expected that CCK‑
‑2/gastrin receptor imaging will become also a val‑
id diagnostic method for a specific and noninva‑
sive staging and follow ‑up of patients with MTC. 
In conclusion, the project represents the first 
step towards establishing a  new, more effi‑
cient strategy for the diagnosis, early detec‑
tion, and therapy of recurrent or metastat‑
ic MTC.  CCK2/gastrin receptor may become 
a new target for radionuclide scintigraphy and 
PRRT (theranostic approach), with nephrotox‑
icity and myelotoxicity minimized by appropri‑
ate measures.
SuPPLEMEnTARy MATERiAL Supplementary ma‑
terial is available with the article at www.pamw.pl.
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to gastrin analogues or gelofusine (Supplemen‑
tary material, Table S4).
Two peptide amounts, both radiolabeled with 
111In (200 +/– 10% MBq), were administered: 
a low amount (10 µg) was used as a safety step 
in the first applications of CP04. If its safety was 
assured, 50 µg (an amount also suitable for PRRT) 
was applied.
The clinical trial consisted of 2 phases. In phase 
1A, the first 4 patients were administered with 
both 10 µg and 50 µg of 111In ‑CP04. In phase 1B, 
only the high peptide amount of 50 µg of 111In‑
‑CP04 was given to the next enrolled patient who 
was randomized to arm 1 or 2 without or with 
coadministration of gelofusine (a nephroprotec‑
tive agent).
All baseline tumor ‑related sign and symptom 
assessments were performed before the start of 
the study. All eligible patients received a central‑
ly assigned number. The tracer was injected with‑
in 14 days after the patient’s inclusion. According 
to the study protocol, subsequent tracer admin‑
istrations were performed at intervals of at least 
2 weeks, providing that no serious adverse events 
were observed.
Dosimetry was planned after each tracer in‑
jection including activity measurements in blood 
and urine, and a series of scintigraphy images: 
dynamic acquisitions of the abdominal region 
(0–30 minutes postinjection), planar whole‑
‑body acquisition (30–60 minutes 4, 24, and 
48 hours postinjection), abdominal and neck or 
mediastinum SPECT ‑CT images (4–5 [option‑
al] and 24 hours postinjection). Blood samples 
were collected for calcitonin and procalcitonin 
measurements.
Eight follow ‑up visits are planned up to 
4 months after the tracer administration to as‑
sess the CP04 safety profile according to the Com‑
mon Terminology Criteria for Adverse Events 
version 4.0.
The study flowcharts are shown in FiguRE 1 and 
in Supplementary material (Table S3). Statistical 
analysis is done both on an intention ‑to ‑treat and 
per ‑protocol basis. The clinical trial was conducted 
according to international standards and the prin‑
ciples of the ICH Harmonized Tripartite Guide‑
lines for Good Clinical Practice, with applicable 
local regulations and the Declaration of Helsinki.
initial results The completed preclinical part of 
the study showed that 111In CP04 can be prepared 
using a simple kit procedure, suitable for clini‑
cal use. According to the study protocol, each of 
the first 4 MTC patients enrolled in the study was 
injected with both peptide amounts (10 µg and 
50 µg) of the gastrin analogue 111In ‑CP04. These 
initial examinations revealed that 111In ‑CP04 was 
safe after intravenous injection (no serious ad‑
verse events were reported) and that the MTC 
metastases could be detected with high sensitiv‑
ity. Biodistribution and preliminary dosimetry 
data also showed 111In ‑CP04 as a promising radio‑
pharmaceutical for PRRT of advanced MTC cases.
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FiguRE 1 Flowchart of the study protocol (phases 1A and 1B) 
Abbreviations: AE, adverse event; CP04, DOTA ‑DGlu ‑DGlu ‑DGlu ‑DGlu ‑DGlu ‑DGlu ‑Ala ‑Tyr ‑Gly ‑Trp ‑Met ‑Asp ‑Phe ‑NH2; CRF, case report form; ICF, 
informed consent form; SAE, serious adverse event
Development of the trial project: study protocol – CRF – ICF – others    
Approvals
Patient recruitment and randomization
Clinical trial
Between patients a minimum of 2 weeks of follow-up for SAE evaluation  
Radiopharmaceutical administration 
of low-dose of 111In-CP04 
Monitoring of patient’s vital signs, acute AE registration  Monitoring of patient’s vital signs, acute AE registration  
Patient imaging and blood sampling: biodistribution and dosimetryPatient imaging and blood sampling: biodistribution and dosimetry
If SAE not present, radiopharmaceutical administration of high-dose 111In-CP04 





Monitoring of patient’s vital signs, acute AE registration Monitoring of patient’s vital signs, acute AE registration 
Patient imaging and blood sampling: biodistribution and dosimetryPatient imaging and blood sampling: biodistribution and dosimetry
If the first three-four patients do not present SAE at the end of 
follow-up, the remaining recruited patients will receive only high-dose 
111In-CP04 (randomized in 2 arms)   
If the first three-four patients present SAE at the end of follow-up, 
the remaining recruited patients
will receive only low-dose 111In-CP04 (no randomization)
Radiopharmaceutical administration 
of low-dose 111In-CP04
Monitoring of patient’s vital signs, acute AE registration 
Patient imaging and blood sampling: biodistribution and dosimetry
Patient follow-up, image evalution, biostatistics  
End of the clinical trial 
Radiopharmaceutical administration 
of high-dose 111In-CP04
Monitoring of patient’s vital signs, acute AE registration Monitoring of patient’s vital signs, acute AE registration
Patient imaging and blood sampling: biodistribution and dosimetry Patient imaging and blood sampling: biodistribution and dosimetry
Radiopharmaceutical administration of high-dose 111In-CP04
Gelofusine
coinfusion
End of the clinical trial 










of low-dose 111In-CP04 
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